Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average […]
StockNews.com downgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from a strong-buy rating to a buy rating in a report issued on Thursday morning. Other analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research report […]
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price target cut by Barclays from $230.00 to $200.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price target would indicate a potential upside of 81.80% from the stock’s […]
Todd Asset Management LLC cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 170,233 shares of the specialty pharmaceutical company’s stock after selling 4,977 shares during the period. Todd […]
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price […]